Allergan tells shareholders to reject Valeant deal

Allergan, the maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate" and that shareholders should reject it.

Allergan said the $53 billion bid from Valeant undervalues the and is not in the best interest of Allergan's shareholders.

Valeant, a Canadian drugmaker, first offered to buy Irvine, California-based Allergan Inc. in April, and has increased its original bid of about $45.6 billion several times, only to be rejected. Valeant teamed up with activist investor Bill Ackman's Pershing Square Capital Management for the bid.

On Friday, Valeant said it was taking its deal directly to Allergan shareholders and allowing them to trade in their stock for 0.83 shares of Valeant and $72 in cash, or another combination.

Allergan's CEO David E.I. Pyott said in a statement that the company can increase shareholder value more than Valeant's bid can.

Shares of Allergan slipped 31 cents to $165.01 in morning trading Monday. Valeant Pharmaceuticals International Inc. shares fell $1.26 to $120.67 in morning trading.


Explore further

Valeant launches hostile $53B bid for Allergan

© 2014 The Associated Press. All rights reserved.

Citation: Allergan tells shareholders to reject Valeant deal (2014, June 23) retrieved 17 July 2019 from https://medicalxpress.com/news/2014-06-allergan-shareholders-valeant.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more